Clinical trial regulatory approval Latin America is one of the most critical factors sponsors and CROs evaluate when planning studies outside the United States. As enrollment numbers continue declining domestically, Latin America has emerged as a reliable and efficient alternative for Phase I through IV studies, offering faster approval timelines, diverse patient populations, and competitive operational costs.<\/p>\n
The shift toward conducting clinical trials outside the United States is driven by several converging factors. Recruitment timelines in the U.S. continue to lengthen while costs rise. Latin America addresses both challenges simultaneously, offering access to large, treatment naive patient populations with high protocol adherence rates and significantly shorter regulatory approval windows than many other international regions.<\/p>\n
Beyond speed, clinical trial regulatory approval Latin America processes provide something increasingly valuable to the FDA and global regulatory bodies: demographic diversity. Data gathered from Hispanic and mixed ethnic populations strengthens the generalizability of study results and supports broader label claims across diverse patient groups. According to ClinicalTrials.gov<\/a>, Latin America accounts for approximately 6 percent of active studies globally despite representing a significant share of the world population, a gap that translates directly into opportunity for sponsors seeking enrollment efficiency and data diversity.<\/p>\n Understanding regulatory timelines is essential when evaluating clinical trial regulatory approval Latin America options. Each country operates through its own regulatory authority and timelines vary significantly.<\/p>\n Colombia<\/strong> operates through INVIMA, the National Institute of Drugs and Food Vigilance. Since April 2016, Colombia reduced its approval timeline from 135 days to approximately 60 days, making it one of the fastest regulatory environments in the region for clinical trial protocol approval. This reduction was achieved by improving internal process efficiency without compromising evaluation quality.<\/p>\n Ecuador<\/strong> operates through ARCSA, the Ecuadorian Sanitary Control Agency. The full clinical trial regulatory approval process from initial submission to final authorization takes approximately 65 days. Ethics committee review occurs at least twice monthly with approval in approximately 20 business days, followed by MOH review of 45 business days. Ecuador’s regulatory infrastructure has developed rapidly in recent years, making it an increasingly attractive destination for sponsors seeking diverse patient populations and efficient timelines.<\/p>\n Peru<\/strong> operates through the INS, the National Institution of Health. Ethics committee review ranges from 20 to 40 days depending on protocol complexity, followed by INS approval of approximately 40 business days. Total timeline runs approximately 15 weeks. INS and ethics committee approvals must be conducted sequentially rather than in parallel, which sponsors should factor into their planning.<\/p>\n Chile<\/strong> operates through the ISP, the National Institute of Public Health, established in 1979. Ethics committee review takes up to 13 weeks, with MOH approval adding approximately 6.5 weeks, for a total startup period of roughly 19 weeks. While Chile’s timeline is the longest among these four countries, its regulatory infrastructure is among the most established in the region.<\/p>\n Regulatory approval timelines represent only one component of successful trial execution in Latin America. Sponsors and CROs unfamiliar with each country’s specific submission requirements, ethics committee schedules, and import licensing processes frequently experience delays that offset the region’s inherent advantages.<\/p>\n Working with experienced local partners who have established relationships with regulatory authorities is the single most effective strategy for maintaining projected timelines. Site selection, patient recruitment infrastructure, and protocol translation all require regional expertise that goes beyond document submission. Sponsors who attempt to navigate clinical trial regulatory approval Latin America processes without local support consistently experience longer than projected timelines regardless of the country selected.<\/p>\n One of the FDA’s core priorities is ensuring clinical trial populations reflect the diversity of patients who will ultimately use the treatments being studied. Latin America addresses this directly. The region’s multicultural populations provide access to demographic groups historically underrepresented in U.S. based trials, including Hispanic patients who represent one of the fastest growing segments of the American population. You can learn more about how diversity strengthens clinical research outcomes at FOMAT’s diversity initiative<\/a>.<\/p>\nRegulatory Timelines by Country<\/h3>\n
Navigating Clinical Trial Regulatory Approval Latin America Successfully<\/h3>\n
The Diversity Advantage<\/h3>\n
How FOMAT Supports Sponsors in Latin America<\/h3>\n